

Please type a plus (+) inside this box -

PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

01/25/99



UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 8907-0078-999 Total Pages

First Named Inventor or Application Identifier

Thomas Quertermous et al.

Express Mail Label No. EL 236 251 638 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
Submit an original, and a duplicate for fee processing
2. ☒ Specification Total Sheets[99]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings *(if filed)*
 - Detailed Description of the Invention *(including drawings, if filed)*
 - Claim(s)
 - Abstract of the Disclosure
3. Drawing(s) (35 USC 113) Total Sheets[32]
4. ☒ Oath or Declaration [2]
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
5. ☒ Incorporation By Reference *(useable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program *(Appendix)*
7. ☒ Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all necessary)*
 - a. ☐ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy).
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document *(if applicable)*
11. Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity ☒ Statement filed in prior application, Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No: 08/659,235 filed 06/05/96.

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

20583

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

NAME

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Anticipated Classification of this application:

Prior application: Examiner KAUFMAN, C.Art Unit 1646

Assistant Commissioner for Patents
 Box PATENT APPLICATION
 Washington, D.C. 20231

Sir:

This is a request for filing a ☐ continuation ☒ divisional application under 37 CFR § 1.53(b), of pending prior application no. 08/659,235 filed on June 5, 1996.

of Thomas Quertermous, Brigid Hogan, H. Ralph Snodgrass, Thomas J. Zupancic
 (inventor(s) currently of record in prior application)

for ANTIBODIES BINDING TO POLYPEPTIDES ENCODED BY DEVELOPMENTALLY-REGULATED
 ENDOTHELIAL CELL LOCUS-1
 (title of invention)

☒ The filing fee is calculated below:

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims.	32	-20	12	\$9.00 each	108.00
Independent	4	-3	1	\$39.00 each	39.00
Basic Fee					760.00
Multiple Dependency Fee If Applicable (\$270.00)					
Total					907.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern					- 453.50
Total Filing Fee					\$ 453.50

2. ☒ Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.
3. ☐ Amend the specification by inserting the following sentence: --This is a divisional of application no. _____, filed _____.--
- 4a. ☐ Transfer the drawings from the prior application to this application and abandon the prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.

- 4b. ☐ New formal drawings are enclosed.
- 4c. ☒ Informal drawings are enclosed.
- 5a. ☐ Priority of application no. _____ filed on _____ in _____ is claimed under 35 U.S.C. §119.
- 5b. ☐ The certified copy has been filed in prior application no. _____, filed _____.
6. ☒ The prior application is assigned of record to Progenitor, Inc. and Vanderbilt University.
- 7a. ☒ The Power of Attorney appears in the original papers in the prior application no. 08/659,235, filed June 5, 1996. (Copies are attached.)
- 7b. ☐ Since the Power of Attorney does not appear in the original papers, a copy of the Power in prior application no. _____, filed _____ is enclosed.
8. ☒ This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no. 08/659,235, filed on June 5, 1996, be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. 08/659,235 is enclosed.
9. ☒ The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from application no. 08/659,235 is the same as the content of the computer readable form submitted in application no. 08/659,235.
10. ☒ Please cancel Claims ~~1-20~~ and ~~28-32~~.
11. ☒ Preliminary Amendment and new claims are attached.

Respectfully submitted,

January 25, 1999
(date)

Brian M. Poissant by Victor H. Lee
Brian M. Poissant Reg. No. 35,750
28,462
(Reg No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, NY 10036
Tel. No. (212) 790-9090

01/25/99
 1c617 U.S. PTO

~~DEVELOPMENTALLY REGULATED ENDOTHELIAL CELL LOCUS 1~~

TABLE OF CONTENTS

		Page
5	1. INTRODUCTION	- 1 -
	2. BACKGROUND OF THE INVENTION	- 1 -
	2.1. ENDOTHELIAL CELL BIOLOGY AND BLOOD VESSEL DEVELOPMENT	- 1 -
10	2.2. EPIDERMAL GROWTH FACTOR-LIKE DOMAIN	- 5 -
	2.3. DISCOIDIN I/FACTOR VIII-LIKE DOMAINS	- 6 -
	3. SUMMARY OF THE INVENTION	- 7 -
	4. BRIEF DESCRIPTION OF THE DRAWINGS	- 8 -
	5. DETAILED DESCRIPTION OF THE INVENTION	- 17 -
15	5.1. THE <i>DEL-1</i> CODING SEQUENCE	- 18 -
	5.2. EXPRESSION OF <i>DEL-1</i> SEQUENCE	- 22 -
	5.3. EXPRESSION SYSTEMS	- 26 -
	5.4. IDENTIFICATION OF CELLS THAT EXPRESS <i>DEL-1</i>	- 32 -
	5.5. USES OF <i>DEL-1</i> ENGINEERED CELL LINES	- 33 -
20	5.6. USES OF <i>DEL-1</i> POLYNUCLEOTIDE	- 39 -
	5.6.1. DIAGNOSTIC USES OF A <i>DEL-1</i> POLYNUCLEOTIDE	- 39 -
	5.6.2. THERAPEUTIC USES OF A <i>DEL-1</i> POLYNUCLEOTIDE	- 39 -
	5.7. USES OF <i>DEL-1</i> PROTEIN	- 42 -
25	6. EXAMPLE: MOLECULAR CLONING OF HUMAN AND MURINE <i>DEL-1</i> NUCLEOTIDE SEQUENCES	- 44 -
	6.1. MATERIALS AND METHODS	- 44 -
	6.1.1. GENERATION OF TRANSGENIC MICE	- 44 -
	6.1.2. MOLECULAR CLONING OF <i>DEL-1</i>	- 44 -
30	6.2. RESULTS	- 45 -
	7. EXAMPLE: TISSUE DISTRIBUTION OF <i>DEL-1</i> GENE EXPRESSION	- 49 -
	7.1. MATERIALS AND METHODS	- 50 -
	7.1.1. WHOLE MOUNT STAINING OF TRANSGENIC MOUSE EMBRYOS	- 50 -
35	7.1.2. NORTHERN BLOT ANALYSIS	- 50 -
	7.1.3. REVERSE TRANSCRIPTION-POLYMERASE REACTION (RT-PCR)	- 51 -

	7.2. RESULTS	- 51 -
	7.2.1 EXPRESSION ANALYSIS BY HISTOCHEMISTRY	- 51 -
	7.2.2. EXPRESSION ANALYSIS BY NORTHERN BLOT	- 54 -
	7.2.3. EXPRESSION ANALYSIS BY RT-PCR	- 57 -
5	8. EXAMPLE: IMMUNOREACTIVITY OF DEL-1 GENE PRODUCT	- 60 -
	8.1. MATERIALS AND METHODS	- 60 -
	8.1.1. ANTIBODY PRODUCTION	- 60 -
	8.1.2. WESTERN BLOT	- 60 -
	8.1.3. IMMUNOHISTOCHEMISTRY	- 61 -
10	8.1.4. TRANSFECTION OF YOLK SAC CELLS	- 61 -
	8.2. RESULTS	- 61 -
	9. EXAMPLE: DEL-1 INHIBITS VASCULAR FORMATION	- 63 -
	9.1 MATERIALS AND METHODS	- 63 -
	9.1.1. ANGIOGENESIS ASSAYS	- 63 -
15	10. EXAMPLE: DEL-1 BINDS TO INTEGRIN ALPHA V BETA 3	- 65 -
	10.1 MATERIALS AND METHODS	- 65 -
	10.1.1. RECOMBINANT DEL-1 PURIFICATION AND REFOLDING	- 65 -
	10.1.2. CELL ADHESION ASSAYS	- 66 -
20	10.2 RESULTS	- 67 -
	11. EXAMPLE: CHROMOSOMAL LOCALIZATION OF HUMAN DEL-1	- 68 -
	12. DEPOSIT OF MICROORGANISMS	- 69 -

25

The present application is a continuation-in-part of co-
pending United States Patent Application Serial No.
08/480,229, filed June 7, 1995, which is incorporated by
reference herein in its entirety.

35